<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2000
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from N/A to N/A
--- ---
Commission File No. 814-55
TECHNOLOGY FUNDING VENTURE PARTNERS IV, AN AGGRESSIVE GROWTH FUND, L.P.
- -----------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 94-3054600
------------------------------ ---------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
2000 Alameda de las Pulgas, Suite 250
San Mateo, California 94403
- ------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
(650) 345-2200
--------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes X No
--- ---
No active market for the units of limited partnership interests
("Units") exists, and therefore the market value of such Units cannot be
determined.
<PAGE>
I. FINANCIAL INFORMATION
Item 1. Financial Statements
BALANCE SHEETS
- --------------
<TABLE>
<CAPTION>
(unaudited)
March 31, December 31,
2000 1999
---------- ------------
<S> <C> <C>
ASSETS
Investments:
Equity investments (cost basis of
$11,306,004 and $11,915,314 for 2000
and 1999, respectively) $25,493,215 15,419,719
Notes receivable (cost basis of
$2,246,176 and $221,307 for 2000 and
1999, respectively) 2,246,176 221,307
---------- ----------
Total investments 27,739,391 15,641,026
Cash and cash equivalents 1,775,307 677,285
Other assets 15,936 1,454
Due from affiliated partnership 970,000 --
---------- ----------
Total assets $30,500,634 16,319,765
========== ==========
LIABILITIES AND PARTNERS' CAPITAL
Accounts payable and accrued expenses $ 65,924 54,345
Due to related parties 44,539 68,554
Other liabilities -- 9,789
---------- ----------
Total liabilities 110,463 132,688
Commitments, contingencies and
subsequent event (Notes 3, 4, 7 and 8)
Partners' capital:
Limited Partners (400,000 Units outstanding) 27,511,340 15,915,048
General Partners 2,878,831 272,029
---------- ----------
Total partners' capital 30,390,171 16,187,077
---------- ----------
Total liabilities and partners' capital $30,500,634 16,319,765
========== ==========
</TABLE>
See accompanying notes to unaudited financial statements.
<PAGE>
STATEMENTS OF OPERATIONS (unaudited)
- -----------------------------------
<TABLE>
<CAPTION>
For the Three Months Ended March 31,
------------------------------------
2000 1999
-------- --------
<S> <C> <C>
Income:
Notes receivable interest $ 30,681 10 284
Short-term investment interest 9,151 6,132
---------- -------
Total income 39,832 16,416
Costs and expenses:
Management fees 40,799 42,685
Individual General Partners'
compensation 5,597 8,669
Operating expenses
Investment operations 55,476 78,758
Administrative and investor services 112,036 137,650
Professional fees 20,122 11,860
Computer services 33,618 28,436
Interest expense 3,732 --
---------- -------
Total operating expenses 224,984 256,704
---------- -------
Total costs and expenses 271,380 308,058
---------- -------
Net operating loss (231,548) (291,642)
Net realized gain (loss) from
sales of equity investments 3,402,598 (30,464)
Realized gain from venture
capital limited partnership
investments 349,238 66,276
---------- -------
Net realized gain (loss) 3,520,288 (255,830)
Change in net unrealized
fair value of equity
investments 10,682,806 (663,774)
---------- -------
Net income (loss) $14,203,094 (919,604)
========== =======
Net income (loss) per Unit $ 28.99 (1.81)
========== =======
</TABLE>
See accompanying notes to unaudited financial statements.
<PAGE>
STATEMENTS OF CASH FLOWS (unaudited)
- -----------------------------------
<TABLE>
<CAPTION>
For the Three Months Ended March 31,
-----------------------------------
2000 1999
---------- ----------
<S> <C> <C>
Cash flows from operating activities:
Interest received $ 10,029 14,764
Cash paid to vendors (99,033) (111,969)
Cash paid to related parties (205,322) (173,835)
Interest paid on short-term
borrowings (3,732) --
---------- ---------
Net cash used by operating activities (298,058) (271,040)
---------- ---------
Cash flows from investing activities:
Purchase of equity investments (1,320,617) (510,208)
Notes receivable issued (2,000,000) (33,333)
Repayments of notes receivable 4,196 198,844
Proceeds from sales of equity
investments 4,537,633 68,372
Distributions from venture capital
limited partnership investments 174,868 --
---------- ---------
Net cash provided (used) by
investing activities 1,396,080 (276,325)
---------- ---------
Net increase (decrease) in cash
and cash equivalents 1,098,022 (547,365)
Cash and cash equivalents at
beginning of year 677,285 1,188,918
---------- ---------
Cash and cash equivalents $ 1,775,307 641,553
at March 31 ========== =========
See accompanying notes to unaudited financial statements.
</TABLE>
<PAGE>
STATEMENTS OF CASH FLOWS (unaudited)(continued)
- -----------------------------------------------
<TABLE>
<CAPTION>
For the Three Months Ended March 31,
------------------------------------
2000 1999
----------- -----------
<S> <C> <C>
Reconciliation of net income (loss) to
net cash used by operating activities:
Net income (loss) $14,203,094 (919,604)
Adjustments to reconcile net income
(loss) to net cash used by operating
activities:
Net realized (gain) loss from sales
of equity investments (3,402,598) 30,464
Realized gain from venture
capital limited partnership
investments (349,238) (66,276)
Change in net unrealized fair value
of equity investments (10,682,806) 663,774
Changes in:
Due to/from related parties (24,015) 43,221
Accrued interest on notes receivable (29,803) --
Accounts payable and accrued expenses 11,579 --
Other changes, net (24,271) (22,619)
--------- ---------
Net cash used by operating activities $ (298,058) (271,040)
========= =========
Supplemental schedule of non-cash
investing activities:
Investment purchase costs due from
affiliated partnership $ 970,000 --
========= =========
</TABLE>
See accompanying notes to unaudited financial statements.
<PAGE>
NOTES TO FINANCIAL STATEMENTS (unaudited)
- ----------------------------------------
1. General
-------
In the opinion of the Managing General Partners, the Balance Sheets as of
March 31, 2000, and December 31, 1999, and the related Statements of
Operations and Statements of Cash Flows for the three months ended March
31, 2000 and 1999, reflect all adjustments which are necessary for a fair
presentation of the financial position, results of operations and cash
flows for such period. These statements should be read in conjunction with
the Annual Report on Form 10-K for the year ended December 31, 1999. The
following notes to financial statements for activity through March 31,
2000, supplement those included in the Annual Report on Form 10-K.
Allocation of income and loss to Limited and General Partners is based on
cumulative income and loss. Adjustments, if any, are reflected in the
current quarter balances.
Partners' Capital Reclassification
- ----------------------------------
Commencing in the fourth quarter of 1999, the Partnership is including the
change in net unrealized fair value of investments in the profits and
losses allocated to partners' capital accounts based on a reevaluation of
the Partnership Agreement. The allocations of the net unrealized fair
value increase (decrease) from cost of investments, and resulting
reclassifications, were determined by applying the provisions of the
Partnership Agreement from the inception of the Partnership. The
reclassification has no effect on total partners' capital or the
Partnership's net income or loss for any period. The reclassifications
resulting from the reevaluation of the Partnership Agreement have the
effect of accelerating the allocation of profits or losses to partners'
capital accounts and, as a result, may permit the acceleration of
distributions to Partners to the extent allowable under the Partnership
Agreement.
The allocation of the net unrealized fair value increase reclassified as of
March 31, 1999 follows:
Net Unrealized
Fair Value
Increase
Limited General From Cost of
Partners Partners Investments Total
-------- -------- -------------- ---------
Partners' capital,
March 31, 1999,
before reclassification $12,977,946 307,889 2,435,553 15,721,388
Allocation of net
unrealized fair value
increase from cost 2,443,951 (8,398) (2,435,553) --
---------- ------- ---------- ----------
Partners' capital,
March 31, 1999,
as reclassified $15,421,897 299,491 -- 15,721,388
========== ======= ========== ==========
2. Financing of Partnership Operations
-----------------------------------
The Managing General Partners expect cash received from the future
liquidation of Partnership investments and future short-term borrowings
will provide the necessary liquidity to fund Partnership operations. The
Partnership may be dependent upon the financial support of the Managing
General Partners to fund operations if future proceeds are not received
timely. The Managing General Partners have committed to support the
Partnership's working capital requirements through short-term advances as
necessary.
3. Related Party Transactions
--------------------------
Related party costs are included in costs and expenses shown on the
Statements of Operations. Related party costs for the three months ended
March 31, 2000 and 1999, were as follows:
<TABLE>
<CAPTION>
2000 1999
-------- --------
<S> <C> <C>
Management fees $ 40,799 42,685
Individual General Partners' compensation 5,597 8,669
Reimbursable operating expenses 134,911 165,702
</TABLE>
Certain reimbursable expenses have been accrued based upon interim
estimates prepared by the Managing General Partners and are adjusted to
actual periodically. There were $30,939 and $55,605 due to related parties
at March 31, 2000 and December 31, 1999 respectively, related to such
expenses.
Amounts payable for management fees were $13,600 and $12,949 at March 31,
2000, and December 31, 1999, respectively. Pursuant to the Partnership
Agreement, quarterly management fees are equal to one quarter of one
percent of the fair value of Partnership assets.
At March 31, 2000, the Partnership had a receivable of $970,000 for
investment purchase costs due from an affiliated partnership. These monies
were received in May 2000.
Officers of the Managing General Partners occasionally receive stock
options as compensation for serving on the Boards of Directors of portfolio
companies. It is the Managing General Partners' policy that all such
compensation be transferred to the investing partnerships. If the options
are non-transferable, they are not recorded as an asset of the Partnership.
Any profit from the exercise of such options will be transferred if and
when the options are exercised and the underlying stock is sold by the
officers. Any such profit is allocated amongst the Partnership and
affiliated partnerships based upon their proportionate investment in the
portfolio company. At March 31, 2000, the Partnership had an indirect
interest in non-transferable Thermatrix Inc. options at an exercise price
higher than the current market value. At March 31, 2000, the Partnership
and affiliated partnerships had an indirect interest in non-transferable
Physiometrix, Inc., Endocare, Inc. and Genstar Therapeutics Corporation
options with a fair market value of $523,490.
<PAGE>
4. Equity Investments
------------------
<TABLE>
A full listing of the Partnership's equity investments at December 31, 1999, is in the 1999 Annual
Report on Form 10-K. Activity from January 1 through March 31, 2000, consisted of:
<CAPTION>
January 1 through March 31, 2000
Principal --------------------------------
Amount or
Investment Shares as of Cost Fair
Industry/Company Position Date March 31, 2000 Basis Value
- ---------------- -------- ---------- -------------- ------- -------
<S> <C> <C> <C> <C> <C>
Balance at January 1, 2000 $11,915,314 15,419,719
---------- ----------
Significant changes:
Communications
- --------------
Efficient Networks,
Inc. Common shares 1999 0 (75,254) (64,487)
Women.com
Networks, Inc. (a) Common shares 1996-1999 148,696 0 (368,513)
Computer Equipment Systems and Software
- ---------------------------------------
Pilot Network
Services, Inc. Common shares 1999 0 (117,381) (166,258)
Environmental
- -------------
Thermatrix Inc. (b) Common shares 1996 1,105,847 0 295,437
Medical/Biotechnology
- ---------------------
ADESSO Specialty
Services Organization,
Inc. (a) (b) Preferred shares 1997-2000 131,265 205,262 1,205,257
CV Therapeutics, Inc. Common shares 1994-1996 0 (108,780) (223,095)
Endocare, Inc. (b) Common shares 1996-1998 46,014 0 496,951
Genstar Therapeutics
Corporation (b) Common shares 1999 438,366 0 3,011,136
Genstar Therapeutics Common share warrants
Corporation (b) at $0.30-$0.74;
expiring 2005-2006 1999 291,667 0 1,979,516
Inhale Therapeutic
Systems, Inc. Common shares 1995-1999 0 (609,998) (1,335,031)
Pharmos Corporation Common shares 1995 0 (45,248) (122,170)
Physiometrix, Inc. (b) Common shares 1996 270,791 0 4,282,018
Sanarus Medical, Inc.
(a) (b) Preferred shares 1999-2000 106,666 110,000 110,000
Venture Capital Limited Partnerships
- ------------------------------------
Various Limited Partnership
interests Various $2,359,914 26,150 907,527
---------- ----------
Total significant changes during the three
months ended March 31, 2000 (615,249) 10,008,288
Other changes, net 5,939 65,208
---------- ----------
Total equity investments at March 31, 2000 $11,306,004 25,493,215
========== ==========
Legend and footnotes:
(a) Equity securities acquired in a private placement transaction;
resale may be subject to certain selling restrictions.
(b) Portfolio company is an affiliate of the Partnership;
resale may be subject to certain selling restrictions.
</TABLE>
Marketable Equity Securities
- ----------------------------
At March 31, 2000, and December 31, 1999, marketable equity securities had
aggregate costs of $1,787,097 and $3,361,363, respectively, and aggregate
market values of $9,791,292 and $3,996,360, respectively. The net
unrealized gains at March 31, 2000, and December 31, 1999, included gross
gains of $8,383,543 and $1,619,144, respectively.
ADESSO Specialty Services Organization, Inc.
- --------------------------------------------
In March 2000, the Partnership purchased 12,218 Series E Preferred shares
for $205,262. The pricing of this round, in which third parties
participated, indicated a $999,995 increase in the fair value of the
Partnership's investment in the company's preferred shares.
CV Therapeutics, Inc.
- ---------------------
In January 2000, the Partnership sold its entire investment in the company
for proceeds of $239,383 and realized a gain of $130,603.
Efficient Networks, Inc.
- ------------------------
In February 2000, the Partnership sold its entire investment in the company
for proceeds of $109,365 and realized a gain of $34,111.
Genstar Therapeutics Corporation
- --------------------------------
In March 2000, the company changed its name from UroGen Corp. to Genstar
Therapeutics Corporation.
Subsequent to March 31, 2000, the fair value of the Partnership's
investment in the company decreased by $634,399 as a result of a decrease
in the publicly traded market price on May 8, 2000.
Inhale Therapeutic Systems, Inc.
- --------------------------------
In March 2000, the Partnership sold its entire investment in the company
for proceeds of $3,450,754 and realized a gain of $2,840,756.
Pharmos Corporation
- -------------------
In January 2000, the Partnership sold its entire investment in the company
for proceeds of $191,382 and realized a gain of $146,134.
Pilot Network Services, Inc.
- ----------------------------
In February 2000, the Partnership sold its entire investment in the company
for proceeds of $298,760 and realized a gain of $181,379.
Sanarus Medical, Inc.
- ---------------------
In February 2000, the Partnership purchased an additional 73,333 Series A
Preferred shares for $110,000.
Venture Capital Limited Partnerships
- ------------------------------------
The Partnership made an additional investment of $26,150 in venture capital
limited partnerships during the quarter ended March 31, 2000. The
Partnership received cash distributions totaling $174,868 from El Dorado
Ventures III, L.P. and Utah Ventures Limited Partnership. The Partnership
received a stock distribution of Medarex, Inc. with a fair value of
$174,370. These distributions were recorded as realized gains. The
Partnership recorded an $881,377 net increase in fair value as a result of
increases in the fair value of the underlying investments of the
partnerships.
Other Equity Investments
- ------------------------
Other significant changes reflected above relate to market value
fluctuations or the elimination of a discount relating to selling
restrictions for publicly traded portfolio companies. Portions of the
Partnership's Thermatrix Inc. and Women.com Networks, Inc. shares are
restricted.
Subsequent to March 31, 2000, the fair value of the Partnership's
investments in Physiometrix, Inc., Thermatrix Inc. and Women.com Networks,
Inc. decreased by $1,790,740, $496,648 and $557,120, respectively, as a
result of a decrease in the publicly traded market price on May 8, 2000.
5. Notes Receivable
----------------
Activity from January 1 through March 31 consisted of:
<TABLE>
2000 1999
-------- --------
<S> <C> <C>
Balance at January 1 $ 221,307 202,777
Notes receivable issued 2,000,000 33,333
Repayments of notes receivable (4,196) (198,844)
Change in interest receivable 29,065 (3,589)
--------- -------
Balance at March 31 $2,246,176 33,677
========= =======
</TABLE>
The interest rate on notes receivable at March 31, 2000 ranged from 8.5% to
50%. All notes are due on demand.
6. Cash and Cash Equivalents
-------------------------
Cash and cash equivalents at March 31, 2000 and December 31, 1999 consisted
of:
<TABLE>
2000 1999
------ ------
<S> <C> <C>
Demand accounts $ 134,966 151,868
Money-Market accounts 1,640,341 525,417
--------- -------
Total 1,775,307 677,285
========= =======
</TABLE>
7. Distributions
-------------
Subsequent to March 31, 2000, a quarterly tax distribution totaling
$1,314,295 was declared and $1,000,000 was paid to the General Partners.
8. Commitments and Contingencies
-----------------------------
The Partnership is a party to financial instruments with off-balance-sheet
risk in the normal course of its business. Generally, these instruments
are commitments for future equity fundings, venture capital limited
partnership investments, equipment financing commitments, or accounts
receivable lines of credit that are outstanding but not currently fully
utilized. As they do not represent current outstanding balances, these
unfunded commitments are properly not recognized in the financial
statements. At March 31, 2000, unfunded investment commitments to
portfolio companies totaled $600,000.
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Liquidity and Capital Resources
- -------------------------------
During the three months ended March 31, 2000, net cash used by operating
activities totaled $298,058. The Partnership paid management fees of
$40,148 to the Managing General Partners and reimbursed related parties for
operating expenses of $159,577. In addition, $5,597 was paid to the
Individual General Partners as compensation for their services. Other
operating expenses of $99,033 were paid, interest paid on short-term
borrowings was $3,732 and interest income of $10,029 was received.
During the three months ended March 31, 2000, the Partnership funded equity
investments of $1,320,617 primarily to portfolio companies in the
medical/biotechnology industry and issued $2,000,000 in notes receivable to
a portfolio company in the computer equipment, systems and software
industry; $970,000 of equity investment purchase costs were receivable from
an affiliated partnership at March 31, 2000. Proceeds from the sales of
equity investments were $4,537,633 and repayments of notes receivable were
$4,196. The Partnership received cash distributions from venture capital
limited partnerships totaling $174,868. At March 31, 2000, the
Partnership's unfunded commitments totaled $600,000.
Cash and cash equivalents at March 31, 2000, were $1,775,307. Future
proceeds from investment sales and future short-term borrowings along with
Managing General Partner support are expected to be adequate to fund
Partnership operations through the next twelve months. Subsequent to March
31, 2000, a quarterly tax distribution totaling $1,314,295 was declared and
$1,000,000 was paid to the General Partners.
Results of Operations
- ---------------------
Current quarter compared to corresponding quarter in the preceding year
- -----------------------------------------------------------------------
Net income was $14,203,094 for the quarter ended March 31, 2000, compared
to net loss of $919,604 during the same period in 1999. The change was
primarily due to an increase of $11,346,580 in the change in net unrealized
fair value of equity investments, a $3,433,062 increase in realized gains
from sales of equity investments, a $282,962 increase in net realized gain
from venture capital limited partnerships and a $31,720 decrease in
operating expenses.
During the quarter ended March 31, 2000, the increase in equity investment
fair value of $10,682,806 was primarily attributable to increases in
portfolio companies in the medical/biotechnology and environmental
industries along with increases in the venture capital limited
partnerships, partially offset by decreases in the communications industry.
During the same period in 1999, the decrease in fair value of equity
investments of $663,774 was primarily attributable to decreases in
portfolio companies in the environmental and microelectronics industries,
partially offset by increases in portfolio companies in the information
technology and medical/biotechnology industries.
Net realized gain from sales of equity investments was $3,402,598 for the
quarter ended March 31, 2000, as compared to a net realized loss of $30,464
for the quarter ended March 31, 1999. The gain in 2000 primarily related
to the sale of Inhale Therapeutic Systems, Inc. (See Note 4.) The loss in
1999 resulted from the sale of Endocardial Solutions, Inc.
During the quarter ended March 31, 2000, the Partnership recorded net
realized gains from venture capital limited partnership investments of
$349,238. During the same period in 1999, there were gains of $66,276.
The gains represented distributions from profits of venture capital limited
partnerships.
Total operating expenses were $224,984 and $256,704 for the quarters ended
March 31, 2000 and 1999, respectively. The decrease is primarily
attributable to decreased investment monitoring activity.
Given the inherent risk associated with the business of the Partnership,
the future performance of the portfolio company investments may
significantly impact future operations.
II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) No reports on Form 8-K were filed by the Partnership during the
quarter ended March 31, 2000.
(b) Financial Data Schedule for the three months ended and as of
March 31, 2000 (Exhibit 27).
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be
signed on its behalf by the undersigned, thereunto duly authorized.
TECHNOLOGY FUNDING VENTURE PARTNERS IV,
AN AGGRESSIVE GROWTH FUND, L.P.
By: TECHNOLOGY FUNDING INC.
Managing General Partner
Date: May 12, 2000 By: /s/Michael R. Brenner
-------------------------------------------
Michael R. Brenner
Vice President
<TABLE> <S> <C>
<ARTICLE>6
<LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM THE FORM 10-Q AS OF MARCH 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
<MULTIPLIER>1
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<PERIOD-TYPE> 3-MOS
<INVESTMENTS-AT-COST> 13,552,180
<INVESTMENTS-AT-VALUE> 27,739,391
<RECEIVABLES> 0
<ASSETS-OTHER> 985,936
<OTHER-ITEMS-ASSETS> 1,775,307
<TOTAL-ASSETS> 30,500,634
<PAYABLE-FOR-SECURITIES> 0
<SENIOR-LONG-TERM-DEBT> 0
<OTHER-ITEMS-LIABILITIES> 110,463
<TOTAL-LIABILITIES> 110,463
<SENIOR-EQUITY> 0
<PAID-IN-CAPITAL-COMMON> 16,202,960
<SHARES-COMMON-STOCK> 400,000
<SHARES-COMMON-PRIOR> 400,000
<ACCUMULATED-NII-CURRENT> 0
<OVERDISTRIBUTION-NII> 0
<ACCUMULATED-NET-GAINS> 0
<OVERDISTRIBUTION-GAINS> 0
<ACCUM-APPREC-OR-DEPREC> 14,187,211
<NET-ASSETS> 30,390,171
<DIVIDEND-INCOME> 0
<INTEREST-INCOME> 39,832
<OTHER-INCOME> 0
<EXPENSES-NET> 271,380
<NET-INVESTMENT-INCOME> (231,548)
<REALIZED-GAINS-CURRENT> 3,751,836
<APPREC-INCREASE-CURRENT> 10,682,806
<NET-CHANGE-FROM-OPS> 14,203,094
<EQUALIZATION> 0
<DISTRIBUTIONS-OF-INCOME> 0
<DISTRIBUTIONS-OF-GAINS> 0
<DISTRIBUTIONS-OTHER> 0
<NUMBER-OF-SHARES-SOLD> 0
<NUMBER-OF-SHARES-REDEEMED> 0
<SHARES-REINVESTED> 0
<NET-CHANGE-IN-ASSETS> 14,203,094
<ACCUMULATED-NII-PRIOR> 0
<ACCUMULATED-GAINS-PRIOR> 0
<OVERDISTRIB-NII-PRIOR> 0
<OVERDIST-NET-GAINS-PRIOR> 0
<GROSS-ADVISORY-FEES> 40,799
<INTEREST-EXPENSE> 3,732
<GROSS-EXPENSE> 275,680
<AVERAGE-NET-ASSETS> 23,288,624
<PER-SHARE-NAV-BEGIN> 39.79
<PER-SHARE-NII> 28.99
<PER-SHARE-GAIN-APPREC> 0
<PER-SHARE-DIVIDEND> 0
<PER-SHARE-DISTRIBUTIONS> 0
<RETURNS-OF-CAPITAL> 0
<PER-SHARE-NAV-END> 68.78
<EXPENSE-RATIO> 1.2
</TABLE>
